Solvonis Therapeutics plc Stock
Stocks
SVNS
GB00BMD1Z199
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
London S.E.
08:29:14 2026-10-08 EDT
|
5-day change | 1st Jan Change | ||
| 0.1070 GBX | +1.90% |
|
-6.96% | -65.48% |
| 10-06 | WINNERS & LOSERS: Celebrus warning; Kenmare gets takeover interest | AN |
| 10-01 | WINNERS & LOSERS: Filtronic SpaceX deal; Light Science revenue warning | AN |
| Market Cap | 7.15M 9.44M 8.43M 7.87M 13.46M 913M 13.56M 94.55M 36.94M 464M 35.43M 34.67M 1.49B | P/E 2026 * |
-2.14x | P/E 2027 * | -2.1x |
|---|---|---|---|---|---|
| Enterprise Value | 5.27M 6.97M 6.22M 5.81M 9.93M 674M 10.01M 69.78M 27.26M 343M 26.15M 25.58M 1.1B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
67.69% | Yield 2026 * |
-
| Yield 2027 * | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| SVNS | Delayed | |
OTC Markets
| SLVNF | Delayed | |
|
Deutsche Boerse AG
| J4I | Delayed | |
|
Börse Stuttgart
| J4I | Delayed | |
|
Boerse Muenchen
| J4I | Real-time |
| 1 day | +1.90% | ||
| 1 week | -6.96% | ||
| Current month | -6.96% | ||
| 1 month | -6.96% | ||
| 3 months | -35.15% | ||
| 6 months | -60.37% | ||
| Current year | -65.48% |
| 1 week | 0.1 |  | 0.12 |
| 1 month | 0.1 | | 0.13 |
| Current year | 0.1 | | 0.33 |
| 1 year | 0.1 | | 0.39 |
| 3 years | 0.1 | | 2.1 |
| 5 years | 0.1 | | 22.46 |
| 10 years | 0.1 | | 22.46 |
| Manager | Title | Age | Since |
|---|---|---|---|
Anthony Tennyson
CEO | Chief Executive Officer | 50 | 2024-05-01 |
Ryan Neates
DFI | Director of Finance/CFO | 34 | - |
David Nutt
CTO | Chief Tech/Sci/R&D Officer | - | 2025-06-02 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Tennyson
BRD | Director/Board Member | 50 | 2024-05-01 |
Nicholas Nelson
CHM | Chairman | 61 | 2024-03-14 |
Dennis Purcell
CHM | Chairman | 71 | 2024-09-25 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/10/24 | Free | Director | 10,500,000 | 8.4159% | ||
| 7/10/24 | Free | Responsable ventes & marketing | 8,694,000 | 6.9684% | ||
| 7/10/24 | Free | Director | 10,500,000 | 8.4159% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.90% | -6.96% | -72.56% | -94.22% | 9.44M | |
| +4.16% | +4.16% | +49.37% | +94.17% | 74.68B | |
| -13.38% | -13.88% | +5.47% | +55.20% | 58.7B | |
| -1.39% | +1.21% | +4.15% | +32.26% | 48.36B | |
| +0.50% | -2.14% | +331.33% | +702.20% | 43.05B | |
| -0.72% | -3.99% | +28.50% | +29.94% | 42.48B | |
| +0.34% | -0.52% | +6.56% | +109.35% | 41.39B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.29B | |
| -0.50% | -3.10% | -10.19% | -14.35% | 23.93B | |
| -3.32% | -10.86% | -37.32% | +316.28% | 22.22B | |
| Average | -1.27% | -2.83% | +31.45% | +128.35% | 38.61B | |
| Weighted average by Cap. | -1.65% | -1.57% | +49.65% | +145.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.57M -4.71M -4.21M -3.93M -6.72M -456M -6.77M -47.23M -18.45M -232M -17.7M -17.32M -746M | -4.01M -5.3M -4.73M -4.41M -7.55M -512M -7.61M -53.05M -20.73M -261M -19.88M -19.45M -838M |
| Net Debt | -1.87M -2.47M -2.21M -2.06M -3.53M -239M -3.55M -24.77M -9.68M -122M -9.28M -9.08M -391M | -6.92M -9.14M -8.16M -7.62M -13.03M -884M -13.13M -91.53M -35.76M -450M -34.3M -33.56M -1.45B |
Employees
6
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-08 | GBX 0.1070 | +1.90% | 12,918,878 |
| 26-10-07 | GBX 0.1050 | +2.44% | 31,662,101 |
| 26-10-06 | GBX 0.1025 | +2.50% | 62,020,807 |
| 26-10-05 | GBX 0.1000 | 0.00% | 38,890,654 |
| 26-10-02 | GBX 0.1000 | -10.71% | 76,586,006 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.001050GBP
Average target price
0.0170GBP
Spread / Average Target
+1,519.05%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- SVNS Stock
Select your edition
All financial news and data tailored to specific country editions
